Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35.012
Filtrar
2.
Isr Med Assoc J ; 22(1): 60-63, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31927808

RESUMEN

BACKGROUND: In this review, the authors re-examine the role of aspirin in the primary prevention of cardiovascular disease. They discuss the history of the use of aspirin in primary prevention, the current guidelines, and the recent evidence surrounding aspirin use as primary prevention in special populations such as those with moderate cardiovascular risk, diabetes mellitus, and the elderly.


Asunto(s)
Aspirina/uso terapéutico , Enfermedades Cardiovasculares/prevención & control , Fibrinolíticos/uso terapéutico , Aspirina/efectos adversos , Fibrinolíticos/efectos adversos , Humanos , Guías de Práctica Clínica como Asunto , Prevención Primaria/métodos
3.
Praxis (Bern 1994) ; 109(1): 31-34, 2020 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-31910767

RESUMEN

CoLaus: Diet, the Forgotten Key to Preventing Cardiovascular Diseases Abstract. Healthy eating is paramount for the prevention and management of cardiovascular diseases. Still, data from the CoLaus study show that dietary management of cardiovascular risk factors and cardiovascular disease is little implemented. Less than one fifth of participants with dyslipidemia reported being on a hypolipidemic diet, and only half of participants with diabetes reported being on an antidiabetic diet. Further, the occurrence of a myocardial infarction was not associated with an improvement in dietary quality.


Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus , Dieta , Dislipidemias , Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus/prevención & control , Dislipidemias/prevención & control , Humanos
4.
BMJ ; 368: l6669, 2020 01 08.
Artículo en Inglés | MEDLINE | ID: mdl-31915124

RESUMEN

OBJECTIVE: To examine how a healthy lifestyle is related to life expectancy that is free from major chronic diseases. DESIGN: Prospective cohort study. SETTING AND PARTICIPANTS: The Nurses' Health Study (1980-2014; n=73 196) and the Health Professionals Follow-Up Study (1986-2014; n=38 366). MAIN EXPOSURES: Five low risk lifestyle factors: never smoking, body mass index 18.5-24.9, moderate to vigorous physical activity (≥30 minutes/day), moderate alcohol intake (women: 5-15 g/day; men 5-30 g/day), and a higher diet quality score (upper 40%). MAIN OUTCOME: Life expectancy free of diabetes, cardiovascular diseases, and cancer. RESULTS: The life expectancy free of diabetes, cardiovascular diseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free of any of these chronic diseases was 23.5 (22.3 to 24.7) years among men who adopted no low risk lifestyle factors and 31.1 (29.5 to 32.5) years in men who adopted four or five low risk lifestyle factors. For current male smokers who smoked heavily (≥15 cigarettes/day) or obese men and women (body mass index ≥30), their disease-free life expectancies accounted for the lowest proportion (≤75%) of total life expectancy at age 50. CONCLUSION: Adherence to a healthy lifestyle at mid-life is associated with a longer life expectancy free of major chronic diseases.


Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Estilo de Vida Saludable/fisiología , Esperanza de Vida , Neoplasias , Conducta de Reducción del Riesgo , Adulto , Consumo de Bebidas Alcohólicas , Índice de Masa Corporal , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/psicología , Diabetes Mellitus Tipo 2/prevención & control , Diabetes Mellitus Tipo 2/psicología , Ejercicio , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/prevención & control , Neoplasias/psicología , Investigación en Enfermería , Estudios Prospectivos , Fumar
5.
Adv Exp Med Biol ; 1216: 115-129, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31894552

RESUMEN

Cardiovascular diseases (CVD) and frailty syndrome are major problems for successful aging. These conditions share many biological aspects, symptoms and adverse effects. Aerobic capacity and muscle strength, that are important characteristics for independence in daily activity, are markedly reduced in older adults with CVD and frailty. There are evidence and recommendations of physical activity and exercises to prevent, treat and manage these conditions. However, the exact dose-response (type, intensity and duration) of exercises is still uncertain for these population. A good physical exercise program should consider the aging physiologic alterations, the vulnerability of the frail syndrome, and the functional-structural changes of CVD. Therefore, a multicomponent program with aerobic and strength training is desirable to improve these conditions. For long term results it is important to older adults with these conditions to change lifestyle and be more active during daily living to reduce sedentary behavior. Being frail with CVD it is not a contraindication for older adults to be engaged in physical activities.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Terapia por Ejercicio , Ejercicio/fisiología , Anciano Frágil , Fragilidad/prevención & control , Anciano , Humanos
6.
Herz ; 45(1): 24-29, 2020 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-31970461

RESUMEN

Cardiovascular diseases are among the leading causes of death worldwide. Apart from a few exceptions heart attack, stroke and peripheral arterial occlusive disease first occur in later adulthood. The cornerstone for these diseases, however, is already laid by accelerated vascular aging in childhood. Apart from pediatric medical preventive check-ups, the medical care of the parents should also be a reason for taking action. A detailed family history enables many conclusions to be drawn about the cardiovascular risk of the next generation This requires targeted diagnostics and appropriate interventions in childhood ranging from lifestyle measures up to pharmaceutical therapy. In this context the current guidelines on the diagnostics and treatment of hypercholesterolemia and arterial hypertension in children and adolescents are also presented.


Asunto(s)
Enfermedades Cardiovasculares , Hipercolesterolemia , Hipertensión , Estilo de Vida , Infarto del Miocardio , Adolescente , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Niño , Humanos , Hipercolesterolemia/complicaciones , Hipercolesterolemia/tratamiento farmacológico , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Infarto del Miocardio/etiología , Infarto del Miocardio/prevención & control , Factores de Riesgo
7.
Herz ; 45(1): 30-38, 2020 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-31993680

RESUMEN

Cardiovascular diseases are the leading cause of death worldwide. Adherence to a healthy lifestyle lifelong is capable of significantly reducing the cardiovascular risk by up to 70% and is therefore a key component in primary prevention of cardiovascular disease. According to the European and American guidelines lifestyle interventions include not smoking, daily physical activity of ≥150 min/week at moderate intensity or 75 min/week for higher intensity physical activity, a cardioprotective nutrition (high proportion of unsaturated fatty acids, low amounts of saturated fatty acids and low salt intake), normal body weight (body mass index 20-25 kg/m2), arterial blood pressure <140/90 mm Hg (optimum <130/80 mm Hg), low-density lipoprotein (LDL)-cholesterol target values depending on the cardiovascular risk and a normal glucose metabolism in type 2 diabetes mellitus with adjustment of a HbA1c to <7%. Lifestyle measures with weight reduction and intensification of physical activity can improve the cardiometabolic risk factors. In this way reduction of the systolic and diastolic blood pressures by approximately 10-15 mm Hg, reduction of HbA1c by approximately 1 % and reduction of triglycerides by ca. 30-40 % are possible. The LDL-cholesterol and lipoprotein(a) levels cannot be easily influenced. Beyond the recommendations for a cardioprotective lifestyle, additional pharmacological therapy may have to be added depending on the cardiovascular risk profile.


Asunto(s)
Enfermedades Cardiovasculares , Diabetes Mellitus Tipo 2 , Estilo de Vida , Prevención Primaria , Enfermedades Cardiovasculares/prevención & control , LDL-Colesterol , Humanos , Factores de Riesgo
8.
Sports Health ; 12(1): 23-28, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31710820

RESUMEN

BACKGROUND: The physical activity vital sign (PAVS) is a simple, validated tool for assessing physical activity in adults that has not been previously studied in pediatrics. HYPOTHESIS: Reported physical activity utilizing the PAVS in pediatric patients should vary according to known associations with physical activity, such as age, sex, blood pressure, and body mass index (BMI). STUDY DESIGN: Cross-sectional study. LEVEL OF EVIDENCE: Level 3. METHODS: All patients within a family medicine residency clinic were assessed via the PAVS from October 1, 2015, to October 31, 2016, including 255 consecutive pediatric patients aged 5 to 18 years. Associations were examined between PAVS, age, sex, blood pressure, and BMI using 1-way analysis of variance. RESULTS: The average PAVS reported for youth (5-11 years) was 384.9 ± 218.1 minutes per week, with 69.5% reporting sufficient physical activity (≥300 minutes per week). Adolescents (12-18 years) reported a mean PAVS of 278.3 ± 199.6 minutes per week, with 51.1% reporting sufficient physical activity. Physical activity was lower in older participants (P < 0.0001) and was higher in male patients (P < 0.03). Higher BMI was associated with lower PAVS (P < 0.005), while lower systolic blood pressure was associated with a greater number of days per week of physical activity (P < 0.005). CONCLUSION: The PAVS successfully identifies accepted associations between age, sex, and BMI in a pediatric population. CLINICAL RELEVANCE: The correlation of the PAVS with age, sex, BMI, and blood pressure may inform future strategies to address and prevent cardiometabolic disease in pediatric patients.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Ejercicio/fisiología , Adolescente , Factores de Edad , Presión Sanguínea/fisiología , Índice de Masa Corporal , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Masculino , Factores Raciales , Factores de Riesgo , Factores Sexuales
10.
Angiology ; 71(1): 10-16, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-30966756

RESUMEN

Cardiovascular disease (CVD) remains the major cause of death and disability worldwide, and residual risk after implementing all current therapies is still high. In this context, the latest (2016) European Cardiology Society/European Atherosclerosis Society guidelines recommend that triglyceride (TG)-lowering drugs should be used in high-risk patients with TGs levels >2.3 mmol/L (200 mg/dL), after lifestyle measures fail to lower them. After several neutral CVD outcome trials with n-3 fatty acids, the Reduction of Cardiovascular Events with EPA-Intervention Trial met its primary end point, that is, among patients with elevated TGs levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower in those who received 4 g of icosapent ethyl daily. In this review, we comment on the findings of previous and recently published randomized controlled CVD outcome trials assessing n-3 fatty acids supplementation. Both efficacy and safety, as well as future perspectives, are discussed.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Suplementos Dietéticos , Dislipidemias/tratamiento farmacológico , Ácido Eicosapentaenoico/análogos & derivados , Ácidos Grasos Insaturados/uso terapéutico , Lípidos/sangre , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/epidemiología , Suplementos Dietéticos/efectos adversos , Dislipidemias/sangre , Dislipidemias/epidemiología , Ácido Eicosapentaenoico/efectos adversos , Ácido Eicosapentaenoico/uso terapéutico , Ácidos Grasos Insaturados/efectos adversos , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , Resultado del Tratamiento
11.
Zhonghua Nei Ke Za Zhi ; 59(1): 18-22, 2020 Jan 01.
Artículo en Chino | MEDLINE | ID: mdl-31887831

RESUMEN

The prevalence of dyslipidemia in Chinese adult is increasing dramatically, which poses a severe challenge to the prevention and treatment of atherosclerotic cardiovascular diseases. In recent years, a series of new research results have been published, providing a lot of new information for the management strategy of dyslipidemia. In order to apply these new research results to clinical practice for the further prevention and treatment of dyslipidemia more reasonably and effectively, the China Cholesterol Education Program (CCEP) Working Committee organized joint expert meeting and revised the "Expert Advice on Prevention and Treatment of Dyslipidemia in China Cholesterol Education Program 2014", in which a new classification standard for cardiovascular risk stratification has been proposed, and the target value of lipid-lowering therapy has been updated.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Colesterol/sangre , Dislipidemias , Guías de Práctica Clínica como Asunto , Adulto , China , Dislipidemias/prevención & control , Dislipidemias/terapia , Humanos , Factores de Riesgo
12.
J Sci Food Agric ; 100(2): 846-854, 2020 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-31646650

RESUMEN

BACKGROUND: Pomegranate has antioxidant, cardioprotective and anti-inflammatory properties. We designed a crossover study aimed at determining if consumption of pomegranate juice (PJ) improves lipid profile and oxidative and inflammatory biomarkers of hemodialysis patients. Forty-one hemodialysis patients were randomly assigned to one of two groups: PJ-treated group receiving 100 mL of natural PJ immediately after their dialysis session three times a week and the control group receiving the usual care. After 8 weeks, a 4-week washout period was established and then the role of the groups was exchanged. Lipid profile, blood pressure and oxidative and inflammatory biomarkers were measured before and after each sequence. RESULTS: Based on the results of intention-to-treat analysis, triglycerides were decreased in PJ condition and increased in the controls. Conversely, high-density lipoprotein cholesterol was increased in PJ and decreased in the control group. Total and low-density lipoprotein cholesterol did not significantly change in either condition. Systolic and diastolic blood pressure significantly decreased in PJ condition. Total antioxidant capacity increased in PJ condition (P < 0.001) and decreased in the controls (P < 0.001). Conversely, malondialdehyde and interleukin-6 decreased in PJ (P < 0.001) and increased in the control group (P ≤ 0.001). The changes of these biomarkers were significantly different between the two conditions. CONCLUSIONS: Eight-week PJ consumption showed beneficial effects on blood pressure, serum triglycerides, high-density lipoprotein cholesterol, oxidative stress and inflammation in hemodialysis patients. © 2019 Society of Chemical Industry.


Asunto(s)
Enfermedades Cardiovasculares/metabolismo , Jugos de Frutas y Vegetales/análisis , Insuficiencia Renal Crónica/dietoterapia , Adulto , Anciano , Presión Sanguínea , Enfermedades Cardiovasculares/inmunología , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/prevención & control , Estudios Cruzados , Femenino , Humanos , Masculino , Malondialdehído/metabolismo , Persona de Mediana Edad , Estrés Oxidativo , Diálisis Renal , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/metabolismo , Insuficiencia Renal Crónica/terapia , Triglicéridos/metabolismo
13.
Semin Oncol ; 46(6): 414-420, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31784040

RESUMEN

Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The discussion then moved to an overview of modern radiation therapy and evolving mechanisms of cardioprotection. The risks and late cardiotoxic effects that must be considered in patients treated prior to the "modern era" were enumerated stressing the importance of long term follow-up of this population.


Asunto(s)
Antineoplásicos Hormonales/efectos adversos , Neoplasias/complicaciones , Neoplasias/terapia , Radioterapia/efectos adversos , Antineoplásicos Hormonales/uso terapéutico , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Terapia Combinada/efectos adversos , Terapia Combinada/métodos , Humanos , Neoplasias/mortalidad , Radioterapia/métodos , Factores de Riesgo
14.
Semin Oncol ; 46(6): 433-436, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31784041

RESUMEN

Guidelines for the diagnosis, management, and surveillance of cancer patients have evolved with the single goal of improving patient care based on established data when available, or in the absence of firm data, on the standard practices of those with broad experience in actual hands-on patient care. Two initiatives intended to disseminate information to cardio-oncologists, were discussed in this session: the first, from the American Society of Clinical Oncology was focused on available data and the confidence level of that data; the second, from The European Society of Cardiology was a position paper. Interestingly, notwithstanding the somewhat different focus, there is considerable agreement between these two initiatives. Nevertheless, guidelines my not be applicable to all afflicted patients, and may raise questions as to when deviations from published standards should be considered. Such deviations may result in allegations of failure to meet standards of care or legal liability.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Enfermedades Cardiovasculares/etiología , Neoplasias/complicaciones , Radioterapia/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cardiotoxicidad , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Manejo de la Enfermedad , Humanos , Terapia Molecular Dirigida/efectos adversos , Terapia Molecular Dirigida/métodos , Neoplasias/terapia , Oncólogos , Rol del Médico , Guías de Práctica Clínica como Asunto , Radioterapia/métodos
15.
Semin Oncol ; 46(6): 408-413, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31784042

RESUMEN

Session III of the Second International Colloquium on Cardio-Oncology focused on the diagnosis, management, and prevention of cardiovascular toxicity of cancer drugs. With a large menu of biomarkers and imaging modalities available to the cardio oncologist, there continues to be no consensus regarding the best use of each modality alone and in combination and whether we can actually prevent early and late cardiotoxicity using these tests to guide a preventive strategy. It has become increasingly clear that early diagnosis and intervention leads to less late cardiotoxicity and fewer cardiac-related events. This can be accomplished by taking a thorough history and performing a goal directed physical examination coupled with use of biomarkers and imaging studies. This session attempted to provide rationale for a current and integrated approach to these issues.


Asunto(s)
Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Enfermedades Cardiovasculares/etiología , Oncología Médica , Neoplasias/complicaciones , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cardiotoxicidad , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Manejo de la Enfermedad , Humanos , Oncología Médica/métodos , Oncología Médica/normas , Terapia Molecular Dirigida/efectos adversos , Terapia Molecular Dirigida/métodos , Neoplasias/terapia
17.
An Bras Dermatol ; 94(6): 691-697, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31789271

RESUMEN

BACKGROUND: Different strategies have been proposed for the cardiovascular risk management of patients with psoriasis. OBJECTIVE: To estimate the cardiovascular risk and evaluate two cardiovascular prevention strategies in patients with psoriasis, analyzing which proportion of patients would be candidates to receive statin therapy. METHODS: A retrospective cohort was selected from a secondary database. All patients >18 years with psoriasis without cardiovascular disease or lipid-lowering treatment were included. The atherosclerotic cardiovascular disease calculator (2018 American College of Cardiology/American Heart Association guidelines) and the Systematic Coronary Risk Evaluation risk calculator (2016 European Society of Cardiology/European Society of Atherosclerosis guidelines) were calculated. The SCORE risk value was adjusted by a multiplication factor of 1.5. The recommendations for the indication of statins suggested by both guidelines were analyzed. RESULTS: A total of 892 patients (mean age 59.9±16.5 years, 54.5% women) were included. The median atherosclerotic cardiovascular disease calculator and Systematic Coronary Risk Evaluation values were 13.4% (IQR 6.1-27.0%) and 1.9% (IQR 0.4-5.2), respectively. According to the atherosclerotic cardiovascular disease calculator, 20.1%, 11.0%, 32.9%, and 36.4% of the population was classified at low, borderline, moderate, or high risk. Applying the Systematic Coronary Risk Evaluation, 26.5%, 42.9%, 20.8%, and 9.8% of patients were stratified as having low, moderate, high, or very high risk, respectively. The proportion of subjects with statin indication was similar using both strategies: 60.1% and 60.9% for the 2018 American College of Cardiology/American Heart Association and 2016 European Society of Cardiology/European Society of Atherosclerosis guidelines, respectively. STUDY LIMITATIONS: This was a secondary database study. Data on the severity of psoriasis and pharmacological treatments were not included in the analysis. CONCLUSION: This population with psoriasis was mostly classified at moderate-high risk and the statin therapy indication was similar when applying the two strategies evaluated.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Enfermedades Cardiovasculares/prevención & control , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Psoriasis/prevención & control , Adulto , Anciano , Enfermedades Cardiovasculares/etiología , Colesterol/sangre , Complicaciones de la Diabetes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Psoriasis/complicaciones , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores Sexuales , Triglicéridos/sangre
18.
Semin Oncol ; 46(6): 426-432, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31791551

RESUMEN

Malignant disease and its treatment carry huge burdens for patients. Some are immediate, in that the disease itself presents as a life threatening event, or the treatment may result in immediate and devastating toxicity. More often the treatment of cancer is associated with more subtle or late events, yet these may impact the quality of life for cancer survivors in a variety of ways. In addition to the physical sequelae of cancer or its treatment, cancer survivors often experience consequences in the form of social or mental incapacity. Session III of this Colloquium on Cardio-Oncology focuses on some of these concerns, both from the perspective of health care providers who strive to minimize the burdens, but also from the viewpoint of the patient him or herself who must deal with the price that must often be paid for increased survival or cure.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Supervivientes de Cáncer , Enfermedades Cardiovasculares/etiología , Neoplasias/complicaciones , Radioterapia/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Manejo de la Enfermedad , Humanos , Incidencia , Neoplasias/terapia , Guías de Práctica Clínica como Asunto , Radioterapia/métodos
19.
Wien Klin Wochenschr ; 131(Suppl 6): 489-590, 2019 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-31792659

RESUMEN

Elevated blood pressure remains a major cause of cardiovascular disease, disability, and premature death in Austria, with suboptimal rates of detection, treatment and control also in recent years. Management of hypertension is a common challenge for physicians with different spezializations. In an attempt to standardize diagnostic and therapeutic strategies and, ultimately, to increase the rate of patients with controlled blood pressure and to decrease the burden of cardiovascular disease, 13 Austrian medical societies reviewed the evidence regarding prevention, detection, workup, treatment and consequences of high blood pressure in general and in various clinical scenarios. The result is presented as the first national consensus on blood pressure. The authors and societies involved are convinced that a joint national effort is needed to decrease hypertension-related morbidity and mortality in our country.


Asunto(s)
Antihipertensivos , Enfermedades Cardiovasculares , Hipertensión , Antihipertensivos/uso terapéutico , Austria , Presión Sanguínea , Enfermedades Cardiovasculares/prevención & control , Consenso , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA